Page 413 - شرور شركات الأدوية

‫ﻣﻼﺣﻈﺎت‬

(3) I recommend the work of John Abraham, collected here: http://

www.sussex.ac.uk/profiles/6.

(4) Owen BM, Braeutigam R. The Regulation Game: Strategic Use of the

Administrative Process. Ballinger Pub Co; 1978. Via Abraham J. On the pro-

hibition of conflicts of interest in pharmaceutical regulation: Precautionary

limits and permissive challenges. A commentary on Sismondo (66:9, 2008,

1909–14) and O’Donovan and Lexchin. Social Science & Medicine. 2010

Mar;70(5):648–51.

(5) http://www.alter-eu.org/sites/default/files/documents/lonngr

en-doc.pdf.

(6) http://www.alter-eu.org/sites/default/files/documents/lonngr

en-doc.pdf.

(7) http://www.alter-eu.org/fr/press-releases/2011/02/25/conflic

t-of-interest-case-involving-ex-ema-director.

(8) http://www.corporateeurope.org/publications/block-revolving-

door.

(9) Lurie, P., Almeida, C., Stine, N., Stine, A. R., & Wolfe, S. M. (2006). Fi-

nancial conflict of interest disclosure and voting patterns at food and drug

administration drug advisory committee meetings. JAMA, 295, 1921e1928.

(10) If you’re interested in starting on this, the following are a good

place to start: http://www.nytimes.com/2009/09/25/health/policy/

25knee.html?_r=1; www.nytimes.com/2005/02/25/politics/25fda.html.

And the work of the Project On Government Oversight is excellent, led by

the researcher who worked on Senator Grassley’s reports into the phar-

maceutical industry: http://www.pogo.org/investigations/public-health/

fda.html; http://pogoblog.typepad.com/pogo/2011/08/fdas-janet-

woodcock-the-substance-behind-her-nonsubstantive-substantive-

ties-to-industry.html.

413